<DOC>
	<DOC>NCT01313494</DOC>
	<brief_summary>The aim of this trial is to determine the efficacy, safety and tolerability of 500 Âµg Roflumilast tablets once daily in patients with COPD in China, Hong Kong, and Singapore.</brief_summary>
	<brief_title>A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore:</brief_title>
	<detailed_description />
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Main Willingness to sign a written informed consent Chronic obstructive pulmonary disease (COPD) according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2009 Chinese or Malay or Indian ethnicity History of chronic obstructive pulmonary disease symptoms for at least 12 months prior to baseline visit V0 Forced expiratory volume in the first second/ Forced vital capacity (FEV1/FVC) ratio (postbronchodilator) &lt; 70% Forced expiratory volume in the first second (FEV1) (postbronchodilator) &lt; 50 % of predicted Former smoker (defined as: smoking cessation at least one year ago) or current smoker both with a smoking history of at least 10 pack years Main Moderate or severe COPD exacerbation and/or COPD exacerbations treated with antibiotics not stopped at V0 Lower respiratory tract infection not resolved 4 weeks prior to the baseline visit V0 History of asthma diagnosis in patients &lt; 40 years of age or relevant lung disease other than COPD Current participation in a pulmonary rehabilitation program or completion of a pulmonary rehabilitation program within 3 months preceding the baseline visit V0 Known alpha1antitrypsin deficiency</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>Roflumilast</keyword>
	<keyword>FEV1</keyword>
	<keyword>China</keyword>
</DOC>